DK0705255T3 - N-morpholino-N-nitrosaminoacetonitril-cyclodextrin-inklusionskomplekser - Google Patents

N-morpholino-N-nitrosaminoacetonitril-cyclodextrin-inklusionskomplekser

Info

Publication number: DK0705255T3
Authority: DK; Denmark
Prior art keywords: complexes; sin; pct; ions; cyclodextrin
Prior art date: 1994-04-26

Application number

DK95918104T

Other languages

Danish (da)

English (en)

Inventor

Joseph Geczy

Lajos Szente

Andrasne Vikmon

Jozsef Szejtli

Julianna Szeman

Original Assignee

Therabel Ind Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-26

Filing date

1995-04-25

Publication date

2000-12-11

1995-04-25 Application filed by Therabel Ind Sa filed Critical Therabel Ind Sa

2000-12-11 Application granted granted Critical

2000-12-11 Publication of DK0705255T3 publication Critical patent/DK0705255T3/da

Links

229920000858 Cyclodextrin Polymers 0.000 title abstract 4
-1 carboxylic acid anions Chemical class 0.000 abstract 4
150000002500 ions Chemical class 0.000 abstract 4
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 4
NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 abstract 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 2
239000003054 catalyst Substances 0.000 abstract 2
229940097362 cyclodextrins Drugs 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
239000007787 solid Substances 0.000 abstract 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 abstract 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 abstract 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 abstract 1
239000003513 alkali Substances 0.000 abstract 1
239000012736 aqueous medium Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000003197 catalytic effect Effects 0.000 abstract 1
150000001768 cations Chemical class 0.000 abstract 1
238000001035 drying Methods 0.000 abstract 1
238000004108 freeze drying Methods 0.000 abstract 1
238000003801 milling Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Materials Engineering (AREA)
Crystallography & Structural Chemistry (AREA)
Polymers & Plastics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Saccharide Compounds (AREA)
Detergent Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK95918104T 1994-04-26 1995-04-25 N-morpholino-N-nitrosaminoacetonitril-cyclodextrin-inklusionskomplekser DK0705255T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU9401183A HU218280B (en)	1994-04-26	1994-04-26	Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
PCT/HU1995/000011 WO1995029172A1 (en)	1994-04-26	1995-04-25	N-morpholino-n-nitrosaminoacetonitril cyclodextrin inclusion complexes

Publications (1)

Publication Number	Publication Date
DK0705255T3 true DK0705255T3 (da)	2000-12-11

Family

ID=10985114

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95918104T DK0705255T3 (da)	1994-04-26	1995-04-25	N-morpholino-N-nitrosaminoacetonitril-cyclodextrin-inklusionskomplekser

Country Status (32)

Country	Link
US (1)	US5698535A (de)
EP (1)	EP0705255B1 (de)
JP (1)	JP3434828B2 (de)
KR (1)	KR960703404A (de)
CN (1)	CN1060164C (de)
AT (1)	ATE197708T1 (de)
AU (1)	AU694219B2 (de)
BG (1)	BG61974B1 (de)
BR (1)	BR9506155A (de)
CA (1)	CA2163539C (de)
CZ (1)	CZ316395A3 (de)
DE (1)	DE69519463T2 (de)
DK (1)	DK0705255T3 (de)
ES (1)	ES2153897T3 (de)
FI (1)	FI956156A7 (de)
GR (1)	GR3035356T3 (de)
HR (1)	HRP950249A2 (de)
HU (1)	HU218280B (de)
IL (1)	IL113491A (de)
LT (1)	LT4167B (de)
LV (1)	LV11543B (de)
MD (1)	MD1419G2 (de)
NO (1)	NO311030B1 (de)
NZ (1)	NZ285149A (de)
PL (1)	PL312183A1 (de)
PT (1)	PT705255E (de)
RO (1)	RO114449B1 (de)
RU (1)	RU2136698C1 (de)
SI (1)	SI0705255T1 (de)
SK (1)	SK155195A3 (de)
WO (1)	WO1995029172A1 (de)
YU (1)	YU25995A (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
CA2391008C (en) *	1999-11-12	2009-12-22	Pitha & Pitha Llc	Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
FR2805462B1 (fr) *	2000-02-24	2003-08-15	Therabel Res	Nouvelle forme galenique orale a liberation prolongee de la molsidomine
TWI321054B (en)	2000-12-19	2010-03-01	California Inst Of Techn	Compositions containing inclusion complexes
EP1219306A1 (de) *	2000-12-29	2002-07-03	Nicox S.A.	Zyklodextrin und NO-abgebende Arzneimittlen enthaltende Zusammensetzungen
RU2332425C2 (ru) *	2002-09-06	2008-08-27	Инсёрт Терапьютикс, Инк.	Полимеры на основе циклодекстрина для доставки терапевтических средств
EP2277551B1 (de)	2002-09-06	2013-05-08	Cerulean Pharma Inc.	Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
WO2004032862A2 (en) *	2002-10-09	2004-04-22	Insert Therapeutics, Inc.	Cyclodextrin-based materials, compositions and uses related thereto
US20080176958A1 (en)	2007-01-24	2008-07-24	Insert Therapeutics, Inc.	Cyclodextrin-based polymers for therapeutics delivery
EP2503888A4 (de) *	2009-11-23	2015-07-29	Cerulean Pharma Inc	Polymere auf cyclodextrinbasis zur therapeutischen verabreichung
US20140094432A1 (en)	2012-10-02	2014-04-03	Cerulean Pharma Inc.	Methods and systems for polymer precipitation and generation of particles
CN111295094A (zh)	2017-10-09	2020-06-16	泰尔茂比司特生物技术有限公司	冻干容器及使用冻干容器的方法
WO2020185916A1 (en)	2019-03-14	2020-09-17	Terumo Bct Biotechnologies, Llc	Lyophilization container fill fixture, system and method of use
CN116249522A (zh) *	2020-07-20	2023-06-09	深圳迈瑞生物医疗电子股份有限公司	一种组合物的血小板解聚用途、解聚试剂及解聚方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3780180A (en)	1971-02-04	1973-12-18	Sandoz Ag	N-substituted amino-n-nitroso-aminoace-tonitriles in the treatment of hypertension
US5039705A (en) *	1989-09-15	1991-08-13	The United States Of America As Represented By The Department Of Health And Human Services	Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5208233A (en) *	1989-09-15	1993-05-04	The United States Of America As Represented By The Department Of Health And Human Services	Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) *	1989-10-18	1993-05-18	The United States Of America As Represented By The Department Of Health And Human Services	Antihypertensive compositions and use thereof
HU211648A9 (en) *	1990-03-28	1995-12-28	Chinoin Gyogyszer Es Vegyeszet	Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
AU668107B2 (en) *	1991-09-24	1996-04-26	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5389675A (en) *	1992-03-27	1995-02-14	The United States Of America As Represented By The Department Of Health And Human Services	Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents

1994
- 1994-04-26 HU HU9401183A patent/HU218280B/hu not_active IP Right Cessation
1995
- 1995-04-25 YU YU25995A patent/YU25995A/sh unknown
- 1995-04-25 CN CN95190353A patent/CN1060164C/zh not_active Expired - Fee Related
- 1995-04-25 PT PT95918104T patent/PT705255E/pt unknown
- 1995-04-25 IL IL11349195A patent/IL113491A/en not_active IP Right Cessation
- 1995-04-25 JP JP52720795A patent/JP3434828B2/ja not_active Expired - Lifetime
- 1995-04-25 DK DK95918104T patent/DK0705255T3/da active
- 1995-04-25 DE DE69519463T patent/DE69519463T2/de not_active Expired - Lifetime
- 1995-04-25 KR KR1019950705912A patent/KR960703404A/ko not_active Ceased
- 1995-04-25 HR HRP9401183A patent/HRP950249A2/hr not_active Application Discontinuation
- 1995-04-25 MD MD95-0440A patent/MD1419G2/ro unknown
- 1995-04-25 EP EP95918104A patent/EP0705255B1/de not_active Expired - Lifetime
- 1995-04-25 SK SK1551-95A patent/SK155195A3/sk unknown
- 1995-04-25 BR BR9506155A patent/BR9506155A/pt not_active Application Discontinuation
- 1995-04-25 PL PL95312183A patent/PL312183A1/xx unknown
- 1995-04-25 WO PCT/HU1995/000011 patent/WO1995029172A1/en not_active Ceased
- 1995-04-25 CZ CZ953163A patent/CZ316395A3/cs unknown
- 1995-04-25 AT AT95918104T patent/ATE197708T1/de active
- 1995-04-25 ES ES95918104T patent/ES2153897T3/es not_active Expired - Lifetime
- 1995-04-25 NZ NZ285149A patent/NZ285149A/en unknown
- 1995-04-25 SI SI9530435T patent/SI0705255T1/xx unknown
- 1995-04-25 RU RU96100760A patent/RU2136698C1/ru active
- 1995-04-25 RO RO95-02248A patent/RO114449B1/ro unknown
- 1995-04-25 AU AU24159/95A patent/AU694219B2/en not_active Expired
- 1995-04-25 CA CA002163539A patent/CA2163539C/en not_active Expired - Lifetime
- 1995-04-25 US US08/571,853 patent/US5698535A/en not_active Expired - Fee Related
- 1995-12-20 FI FI956156A patent/FI956156A7/fi not_active Application Discontinuation
- 1995-12-22 LV LVP-95-383A patent/LV11543B/en unknown
- 1995-12-22 NO NO19955283A patent/NO311030B1/no not_active IP Right Cessation
- 1995-12-22 LT LT95-133A patent/LT4167B/lt not_active IP Right Cessation
1996
- 1996-01-26 BG BG100313A patent/BG61974B1/bg unknown
2001
- 2001-02-02 GR GR20010400181T patent/GR3035356T3/el unknown

Also Published As

Publication number	Publication date
EP0705255A1 (de)	1996-04-10
EP0705255B1 (de)	2000-11-22
IL113491A0 (en)	1995-07-31
FI956156A0 (fi)	1995-12-20
PT705255E (pt)	2001-05-31
MD1419G2 (ro)	2000-11-30
LV11543B (en)	1996-12-20
HU218280B (en)	2000-07-28
HRP950249A2 (en)	1997-10-31
RO114449B1 (ro)	1999-04-30
AU2415995A (en)	1995-11-16
NZ285149A (en)	1998-06-26
LV11543A (lv)	1996-10-20
NO955283L (no)	1995-12-22
BG61974B1 (bg)	1998-11-30
CA2163539A1 (en)	1995-11-02
HUT70750A (en)	1995-10-30
ES2153897T3 (es)	2001-03-16
DE69519463D1 (de)	2000-12-28
HU9401183D0 (en)	1994-07-28
FI956156A7 (fi)	1995-12-20
NO955283D0 (no)	1995-12-22
AU694219B2 (en)	1998-07-16
SI0705255T1 (en)	2001-04-30
MD1419F2 (en)	2000-02-29
NO311030B1 (no)	2001-10-01
YU25995A (sh)	1998-08-14
PL312183A1 (en)	1996-04-01
US5698535A (en)	1997-12-16
RU2136698C1 (ru)	1999-09-10
BR9506155A (pt)	1996-04-16
JP3434828B2 (ja)	2003-08-11
LT95133A (en)	1996-10-25
IL113491A (en)	2002-03-10
LT4167B (en)	1997-06-25
CN1128028A (zh)	1996-07-31
CA2163539C (en)	2003-04-01
JPH09503546A (ja)	1997-04-08
WO1995029172A1 (en)	1995-11-02
GR3035356T3 (en)	2001-05-31
MD950440A (ro)	1997-10-31
ATE197708T1 (de)	2000-12-15
CZ316395A3 (en)	1996-05-15
DE69519463T2 (de)	2001-06-28
SK155195A3 (en)	1997-05-07
CN1060164C (zh)	2001-01-03
KR960703404A (ko)	1996-08-17
BG100313A (bg)	1996-07-31

Publication	Publication Date	Title
NO955283L (no)	1995-12-22	SIN-1A cyklodekstrin-inklusjons-komplekser
RU95120098A (ru)	1997-10-20	Фосфонометилированные хитозаны
KR910011645A (ko)	1991-08-07	수성 베타 수산화 코발트(ii) 및 그의 제조방법
PT84491B (pt)	1989-11-10	Processo de preparacao de sulfato de dermatano de alta pureza, e de composicoes farmaceuticas que o contem
RU96100760A (ru)	1998-03-27	Новые комплексы включения sin-1a и циклодекстрина
GB1389621A (en)	1975-04-03	Salts of 3-hydroxy-2-hydroxy-methyl-propanesulphonic acid-1 and a process for their preparation
US5466846A (en)	1995-11-14	Process for preparation of stable aqueous solutions of zirconium chelates
Northrop	1937	The formation of enzymes
GB1270448A (en)	1972-04-12	Heavy metal complexes of cephalosporin c and process for the isolation of cephalosporin c in the form of such complexes
KR900009089A (ko)	1990-07-02	알카토닌 수용액 조성물
SU1353727A1 (ru)	1987-11-23	Способ получени кристаллического двойного фосфата титана и магни общей формулы @ -TI MG(РО @ ) @ 3Н @ О
GB1317159A (en)	1973-05-16	Manufacture of cephalosporin compounds
Goman et al.	2021	Precipitation of calcium oxalate monohydrate and dihydrate with gallic acid
JP3228831B2 (ja)	2001-11-12	カルシウムイオンの溶出が抑制されたリン酸水素カルシウムの製造方法
JPS6236093A (ja)	1987-02-17	液体肥料の製造方法
JPS61227507A (ja)	1986-10-09	葉の成長剤乾燥組成物
KR970073342A (ko)	1997-12-10	은(Ag) 함유 무기 항균제의 제조방법
JPH0655853B2 (ja)	1994-07-27	可溶性テルル組成物
JPH0280311A (ja)	1990-03-20	水酸アパタイトの湿式合成法
JPH0959165A (ja)	1997-03-04	安定化ポリヨウ化物製剤の製造法
JPS6118796A (ja)	1986-01-27	アデノシン５′―三リン酸の製造方法
JPS61157502A (ja)	1986-07-17	易分散性カルボキシアルキルヒドロキシアルキルセルロ−スの製造法
JPS63229057A (ja)	1988-09-22	安定な第一鉄化合物水溶液
JPS6230794A (ja)	1987-02-09	グリチルリチン濃厚水溶液の製造法
KR940008679A (ko)	1994-05-16	수용성 비스무스 화합물의 제조방법